Smoking and related problems in the practice of a cardiologist

cardiovascular risk, hypertension, combination therapy

1. Kannel W.B. Update on the role of cigarette smoking in coronary artery disease // Am. Heart J. - 1991. - Vol. 101, № 3. - P. 319-328.

2.

3. Craig W.Y., Palomaki G.E., Haddow J.E. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data //Br. Med. J. - 1989. - Vol. 298, № 6676. - P. 784-788.

4.

5. Ernst E., Resch K. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature // Ann. Intern. Med. - 1993. - Vol. 118, № 12. - P. 207-219.

6.

7. Nowak J., Murray J.J., Oates J.A., FitzGerald G.A. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes // Circulation. - 1987. - Vol. 76, № 1. - P. 6-14.

8.

9. Waters D., Lespérance J., Gladstone P. et al. for the CCAIT Study Group. Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy // Circulation. - 1996. - Vol. 94, № 4. - P. 614-621.

10.

11. Pittilo R.M. Cigarette smoking and endothelial injury: a review // Adv. Exp. Med. Biol. - 1990. - Vol. 273. - P. 61-78.

12.

13. Bressler P., Bailey S.R., Matsuda M., DeFronzo R.A. Insulin resistance and coronary artery disease // Diabetologia. - 1996. - Vol. 39, № 11. - P. 1345-1350.

14.

15. Bao W., Srinivasan S.R., Berenson G.S. Persistent elevation of plasma insulin levels is associated with increased cardio-vascular risk in children and young adults. The Bogalusa Heart Study // Circulation. - 1996. - Vol. 93, № 1. - P. 54-59.

16.

17. Attvall S., Fowelin J., Lager I., vonSchenck H., Smith U. Smoking induces insulin resistance - a potential link with the insulin resistance syndrome // J. Intern. Med. - 1993. - Vol. 233, № 4. - P. 327-332.

18.

19. Facchini F.S., Hollenbeck C.B., Jeppesen J.J. et al. Insulin resistance and cigarette smoking // Lancet. - 1992. - Vol. 339, № 8802. - P. 1128-1130.

20.

21. Griendling K.K., Alexander R.W. Oxidative stress and cardiovascular disease // Circulation. - 1997. - Vol. 96, № 10. - P. 3264-3265.

22.

23. Stehouwer C.D.A., Lambert J., Donker A.J.M., van Hirsbergh V.W.M. Endothelial dysfunction and pathogenesis of diabetic angiopathy // Cardiovasc. Res. - 1997. - Vol. 34, № 1. - P. 55-68.

24.

25. Adams M.R., Jessup W., Celermajer D.S. Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: reversibility with oral L-arginine but not vitamin C // J. Am. Coll. Cardiol. - 1997. - Vol. 29, № 3. - P. 491-497.

26.

27. Summers L.K.M., Samra J.S., Frayn K.N. Impaired postprandial tissue regulation of blood flow in insulin resistance: a determinant of cardiovascular risk? // Atherosclerosis. - 1999. - Vol. 147, № 1. - P. 11-15.

28.

29. Higashi Y., Oshima T., Sasaki N. et al. Relationship between insulin resistance and endothelium-dependent vascular relaxation in patients with essential hypertension // Hypertension. - 1997. - Vol. 29, № 1, Pt. 2. - P. 280-285.

30.

31. Pepine C.J., Schlaifer J.D., Mancini G.B. et al. Influence of smoking status on progression of endothelial dysfunction. TREND Investigators. Trial on reversing endothelial dysfunction // Clin. Cardiol. - 1998. - Vol. 21, № 5. - P. 331-334.

32.

33. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M. et al. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial // J.

34.

35. Am. Med. Assoc. - 2003. - Vol. 290, № 21. - P. 2805-2816.

36.

37. Ruggenenti P., Fassi A., Parvanova Ilieva A. et al. for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes // N. Engl. J. Med. - 2004. - Vol. 351, № 19. - P. 1941-1951.

38.

39. Bangalore S., Messerli F.H., Cohen J.D. et al. INVEST Investigators. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy // Am. Heart J. - 2008. - Vol. 156, № 2. - P. 241-247. 20. Widimský J. The fixed combination of verapamil SR/trandolapril // Expert Opin. Pharmacother. - 2000. - Vol. 1, № 3. - P. 515-535.

40.

41. Karlberg B.E., Andrup M., Odén A. Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialists // Blood Press. - 2000. - Vol. 9, № 2-3. - P. 140-145.